294 related articles for article (PubMed ID: 35516806)
1. A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.
Muddapu VR; Vijayakumar K; Ramakrishnan K; Chakravarthy VS
Front Neurosci; 2022; 16():797127. PubMed ID: 35516806
[TBL] [Abstract][Full Text] [Related]
2. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms.
Robertson GS; Robertson HA
J Neurosci; 1989 Sep; 9(9):3326-31. PubMed ID: 2795165
[TBL] [Abstract][Full Text] [Related]
3. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
Ahlers-Dannen KE; Spicer MM; Fisher RA
Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
[TBL] [Abstract][Full Text] [Related]
4. A Computational Model of Loss of Dopaminergic Cells in Parkinson's Disease Due to Glutamate-Induced Excitotoxicity.
Muddapu VR; Mandali A; Chakravarthy VS; Ramaswamy S
Front Neural Circuits; 2019; 13():11. PubMed ID: 30858799
[TBL] [Abstract][Full Text] [Related]
5. A Multi-Scale Computational Model of Excitotoxic Loss of Dopaminergic Cells in Parkinson's Disease.
Muddapu VR; Chakravarthy VS
Front Neuroinform; 2020; 14():34. PubMed ID: 33101001
[TBL] [Abstract][Full Text] [Related]
6. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
[TBL] [Abstract][Full Text] [Related]
7. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Pinna A; Costa G; Serra M; Contu L; Morelli M
Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
[TBL] [Abstract][Full Text] [Related]
8. Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression.
Seiler JL; Zhuang X; Nelson AB; Lerner TN
Exp Neurol; 2024 Apr; 374():114693. PubMed ID: 38242300
[TBL] [Abstract][Full Text] [Related]
9. Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3
Suarez LM; Alberquilla S; García-Montes JR; Moratalla R
J Neurosci; 2018 Apr; 38(15):3619-3630. PubMed ID: 29483281
[TBL] [Abstract][Full Text] [Related]
10. Dual effects of L-DOPA on nigral dopaminergic neurons.
Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
[TBL] [Abstract][Full Text] [Related]
11. Molsidomine, a nitric oxide donor, modulates rotational behavior and monoamine metabolism in 6-OHDA lesioned rats treated chronically with L-DOPA.
Lorenc-Koci E; Czarnecka A; Lenda T; Kamińska K; Konieczny J
Neurochem Int; 2013 Dec; 63(8):790-804. PubMed ID: 24090640
[TBL] [Abstract][Full Text] [Related]
12. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
[TBL] [Abstract][Full Text] [Related]
13. Effects of subthalamic nucleus deep brain stimulation on neuronal spiking activity in the substantia nigra pars compacta in a rat model of Parkinson's disease.
Sahai S; Effendi ET; Mahoney EC; Tucker HR; Moolick BJ; Mamone G; Mikkilineni S; Gupta M; Nicholson A; Chua FY; Akhtar K; Hirschstein Z; Molho ES; Pilitsis JG; Shin DS
Neurosci Lett; 2020 Nov; 739():135443. PubMed ID: 33141067
[TBL] [Abstract][Full Text] [Related]
14. Neonatal 6-OHDA lesion of the SNc induces striatal compensatory sprouting from surviving SNc dopaminergic neurons without VTA contribution.
Tanguay W; Ducrot C; Giguère N; Bourque MJ; Trudeau LE
Eur J Neurosci; 2021 Oct; 54(7):6618-6632. PubMed ID: 34470083
[TBL] [Abstract][Full Text] [Related]
15. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
[TBL] [Abstract][Full Text] [Related]
16. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.
De Deurwaerdère P; Di Giovanni G; Millan MJ
Prog Neurobiol; 2017 Apr; 151():57-100. PubMed ID: 27389773
[TBL] [Abstract][Full Text] [Related]
17. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
[TBL] [Abstract][Full Text] [Related]
18. A Multiscale, Systems-Level, Neuropharmacological Model of Cortico-Basal Ganglia System for Arm Reaching Under Normal, Parkinsonian, and Levodopa Medication Conditions.
Nair SS; Muddapu VR; Chakravarthy VS
Front Comput Neurosci; 2021; 15():756881. PubMed ID: 35046787
[TBL] [Abstract][Full Text] [Related]
19. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
